Regulatory Update — Week of May 22, 2023

Over the past week, the FDA issued a notice of Abbott’s withdrawal of Cylert NDA, draft guidance on generally accepted scientific knowledge and final guidance on covariates in randomized clinical trials.
Source: Drug Industry Daily